Investors who lost money on Outset Medical, Inc. (OM) should contact Levi & Korsinsky about pending Class Action - OM

Core Viewpoint - A class action securities lawsuit has been filed against Outset Medical, alleging securities fraud that affected investors between August 1, 2022, and August 7, 2024 [1] Group 1: Allegations of Fraud - The lawsuit claims that Outset Medical made false statements regarding its Tablo products, which are used in dialysis care, specifically marketing them for continuous renal replacement therapy without FDA approval [2] - It is alleged that Outset Medical was likely to submit an additional 510(k) application for the Tablo products due to the lack of approved indications [2] - The complaint indicates a substantial risk that Outset Medical would have to cease sales of the Tablo products pending FDA approval of additional indications [2] - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2] - Positive statements made by the defendants about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses in Outset Medical during the relevant time frame have until October 28, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]